698-P: Glycemic Improvement in 11,273 Adults with Type 1 Diabetes (T1D) Using the Omnipod Insulin Management System over First 90 Days of Use

Real-world evidence describing clinical outcomes in people with T1D using various devices is important to support decision-making. This retrospective study characterized patient-reported clinical outcomes in adults in the United States with T1D before (baseline) and 90 days after (follow-up) the initiation of a tubeless insulin pump (Omnipod® or Omnipod DASH® Insulin Management System). The primary outcome was change in self-reported HbA1c level from baseline to follow-up. Secondary outcomes were change in self-reported total daily dose (TDD) of insulin and self-reported frequency of hypoglycemic events (HE) per week (#/week Disclosure G. Aleppo: Consultant; Self; Dexcom, Inc., Insulet Corporation, Research Support; Self; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Novo Nordisk. D. Desalvo: Consultant; Self; Insulet Corporation, Research Support; Self; Insulet Corporation, Speaker’s Bureau; Self; Dexcom, Inc. F. Lauand: Employee; Self; Insulet Corporation. L. M. Huyett: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. J. Jantz: Employee; Self; Insulet Corporation. A. Chang: Employee; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. T. Ly: Employee; Self; Insulet Corporation. Funding Insulet Corporation